Predictive models for hERG potassium channel blockers.

We report here a general method for the prediction of hERG potassium channel blockers using computational models generated from correlation analyses of a large dataset and pharmacophore-based GRIND descriptors. These 3D-QSAR models are compared favorably with other traditional and chemometric based HQSAR methods.

[1]  J. Mitcheson,et al.  Molecular determinants of high-affinity drug binding to HERG channels. , 2003, Current opinion in drug discovery & development.

[2]  A. Cavalli,et al.  Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers. , 2002, Journal of medicinal chemistry.

[3]  Kamilla Angelo,et al.  New Binding Site on Common Molecular Scaffold Provides HERG Channel Specificity of Scorpion Toxin BeKm-1* 210 , 2002, The Journal of Biological Chemistry.

[4]  Paul B Bennett,et al.  High throughput ion-channel pharmacology: planar-array-based voltage clamp. , 2003, Assay and drug development technologies.

[5]  W. Crumb,et al.  Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. , 2002, The Journal of pharmacology and experimental therapeutics.

[6]  S. Pickett,et al.  GRid-INdependent descriptors (GRIND): a novel class of alignment-independent three-dimensional molecular descriptors. , 2000, Journal of medicinal chemistry.

[7]  Brian B. Goldman,et al.  A model for identifying HERG K+ channel blockers. , 2004, Bioorganic & medicinal chemistry.

[8]  Andreas Ebneth,et al.  HTS techniques to investigate the potential effects of compounds on cardiac ion channels at early-stages of drug discovery. , 2003, Current opinion in drug discovery & development.

[9]  M. Sanguinetti,et al.  A mechanistic link between an inherited and an acquird cardiac arrthytmia: HERG encodes the IKr potassium channel , 1995, Cell.

[10]  Robert Pearlstein,et al.  Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior. , 2003, Journal of medicinal chemistry.

[11]  Jules C Hancox,et al.  The Low-Potency, Voltage-Dependent HERG Blocker Propafenone—Molecular Determinants and Drug Trapping , 2004, Molecular Pharmacology.

[12]  C. January,et al.  [3H]dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen. , 2001, European journal of pharmacology.

[13]  Maurizio Recanatini,et al.  Safety of Non-Antiarrhythmic Drugs that Prolong the QT Interval or Induce Torsade de Pointes , 2002, Drug safety.

[14]  Roy J. Vaz,et al.  Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches. , 2003, Bioorganic & medicinal chemistry letters.

[15]  G. Keserü.  Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods. , 2003, Bioorganic & medicinal chemistry letters.

[16]  Rita R. Patel,et al.  A High-Throughput HERG Potassium Channel Function Assay: An Old Assay with a New Look , 2002, Drug development and industrial pharmacy.

[17]  Ferran Sanz,et al.  Incorporating molecular shape into the alignment-free Grid-Independent Descriptors. , 2004, Journal of medicinal chemistry.

[18]  T. Garyantes,et al.  Development and Evaluation of High Throughput Functional Assay Methods for hERG Potassium Channel , 2001, Journal of biomolecular screening.

[19]  W. Crumb,et al.  Validation of a [3H]astemizole binding assay in HEK293 cells expressing HERG K+ channels. , 2004, Journal of pharmacological sciences.

[20]  I Kodama,et al.  Open channel block of HERG K(+) channels by vesnarinone. , 2001, Molecular pharmacology.

[21]  D. Rampe,et al.  High affinity blockade of the HERG cardiac K(+) channel by the neuroleptic pimozide. , 2000, European journal of pharmacology.

[22]  M. Jiang,et al.  Mapping the Binding Site of a Humanether-a-go-go-related Gene-specific Peptide Toxin (ErgTx) to the Channel's Outer Vestibule* , 2002, The Journal of Biological Chemistry.

[23]  Abby L. Parrill,et al.  Rational drug design : novel methodology and practical applications , 1999 .

[24]  Gisbert Schneider,et al.  A Virtual Screening Method for Prediction of the hERG Potassium Channel Liability of Compound Libraries , 2002, Chembiochem : a European journal of chemical biology.